Robert Koch Institute, Berlin, Germany.
Euro Surveill. 2021 Oct;26(41). doi: 10.2807/1560-7917.ES.2021.26.41.2100920.
The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE against different endpoints. Pooled VE was 63.1% (95% confidence interval (CI): 40.9-76.9) against asymptomatic infection, 75.7% (95% CI: 69.3-80.8) against symptomatic infection and 90.9% (95% CI: 84.5-94.7) against hospitalisation. Compared with the Alpha variant, VE against mild outcomes was reduced by 10-20%, but fully maintained against severe COVID-19.
德尔塔变异株已成为 SARS-CoV-2 的主要流行株。我们总结了 17 项研究中关于 COVID-19 疫苗有效性 (VE) 的证据，这些研究调查了针对不同终点的 VE。针对无症状感染的疫苗有效性为 63.1%（95%置信区间：40.9-76.9），针对有症状感染的疫苗有效性为 75.7%（95%置信区间：69.3-80.8），针对住院的疫苗有效性为 90.9%（95%置信区间：84.5-94.7）。与阿尔法变异株相比，针对轻症的 VE 降低了 10-20%，但对重症 COVID-19 仍完全有效。
Zotero 插件